对于为何提前换届和经营业绩等问题，记者致电宝莱特并发去采访邮件，接线工作人员表示，暂无更多 回应。 距本届董事会任期届满尚有半年时间 宝莱特成立于1993年，总部位于广东省珠海市，控股股东和实际控制人为燕金元、王石夫妇，公司主营 业务为医疗器械产品研发、生产、销售、服务，主要涵盖生命信息与支持和肾病医疗两大业务板块。其 中，生命信息与支持板块主要产品为监护仪设备、心电图机、输注液泵、脉搏血氧仪、监护系统、可穿 戴医疗产品等，目前监护设备已覆盖数千家医疗机构。 7月16日晚间，血透龙头宝莱特（300246.SZ，股价9.11元，市值24.1亿元）发布董事会提前换届公告 称，第八届董事会任期即将于2025年12月届满，结合公司实际情况，公司拟开展董事会提前换届选举工 作。 肾病医疗板块，主要产品为血液透析设备（机）、血液透析器、透析液过滤器、血液透析粉/透析液、 透析管路、穿刺针、消毒液、透析用制水设备等，广泛应用于急慢性肾功能衰竭领域的治疗。 根据公告，宝莱特第八届董事会非独立董事陈坚、廖伟、唐文普将不再担任公司非独立董事职务，陈坚 拟提名为第九届董事会独立董事。此次提前换届后，宝莱特第九届董事会拟由9名董事组 ...

Core Viewpoint - The company reported significant declines in revenue and profit for 2024, reflecting operational pressures and strategic adjustments in various business segments [1][2][3] Financial Performance - In 2024, the company achieved revenue of 6.103 billion yuan, a decrease of 23.52%, and a net profit attributable to shareholders of 247 million yuan, down 80.37% [1] - The first quarter of 2025 saw revenue of 1.736 billion yuan, a decline of 9.67%, with a net profit of 379 million yuan, down 21.44% [1] - The gross margin for 2024 decreased by 3.36 percentage points to 60.88% due to policy impacts on the pharmaceutical sector and strategic adjustments in the medical device segment [1] Business Segment Analysis - The pharmaceutical segment reported revenue of 3.49 billion yuan for raw materials, down 14.99%, and 1.409 billion yuan for formulations, down 46.50% [1] - The medical device segment generated revenue of 3.326 billion yuan, reflecting a strategic shift and operational challenges [1][2] - The medical services and health management segment achieved revenue of 1.019 billion yuan, down 19.24%, with notable growth in the Hefei Cardiovascular Hospital [3] Strategic Focus and Innovation - The company is focusing on innovation and internationalization, with new products in the interventional device field receiving approval [4] - The R&D pipeline includes various medical products expected to contribute significantly to future revenue [4] Future Outlook - The company is positioned as a leading player in the cardiovascular sector, with strategic adjustments in the pharmaceutical business and a focus on consumer healthcare expected to drive growth [5] - Projected net profits for 2025-2027 are 999 million yuan, 1.197 billion yuan, and 1.415 billion yuan, representing substantial growth rates [5]

戴维医疗（300314）公告，全资子公司维尔凯迪近日取得浙江省药品监督管理局颁发的3项《受理通知 书》。受理号分别为械受20254019912、械受20254019913、械受20254019722。产品包括一次性使用肺 结节定位穿刺针、一次性使用电子输尿管肾盂内窥镜导管、便携式电子内窥镜图像处理器，注册分类均 为II类。上述品种注册申请受理对公司近期业绩不会产生影响。 ...

三鑫医疗4月27日晚间发布2025年第一季度报告，报告期内实现营业收入3.61亿元，同比增长8.88%；归 属于上市公司股东的净利润5372.57万元，同比略增0.20%；扣非净利润5050.37万元，同比增长7.93%； 经营活动净现金流5667.06万元，同比增长60.02%；净利润现金比率为105.48%，延续了较高的盈利质 量。在业绩整体保持稳健的同时，三鑫医疗持续加大对新产品、新技术的研发投入，一季度公司研发费 用投入1625.01万元，同比增长33.96%，为高质量发展蓄势赋能。 (原标题：境内外市场并行拓展三鑫医疗（300453）2025年一季度营收稳步增长) 在国内市场，三鑫医疗血液透析器、血液透析管路、动静脉瘘穿刺针等主要血液透析产品中选"二十三 省"血液透析耗材联盟集采和"京津冀3+N"血液透析耗材联盟集采，在获得约定采购量的同时，公司还 具备参与待分配采购量的分配资格，且部分产品的报价上具备较大优势,在集采前占有率相对较低的部 分区域获得新突破，重点产品整体市场份额得以稳步提升。根据相关带量采购文件规定，带量采购执行 时间均在1年及以上，到期后可根据采购和供应等实际情况延长采购期限，有利 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook on the company's performance and growth potential [1][3]. Core Viewpoints - The company has ended inventory destocking with significant localization effects and is experiencing high growth in overseas markets. However, domestic sales are impacted by medical industry regulations, leading to a slowdown in growth [3]. - In 2024, the company achieved a revenue of 1.509 billion yuan, a year-on-year increase of 8.76%, and a net profit of 219 million yuan, up 13.98% year-on-year. The first quarter of 2025 saw a revenue of 348 million yuan, reflecting a year-on-year growth of 12.6% [1][3]. - The company is expanding its market presence in Mexico, Europe, and emerging markets in South America and Southeast Asia, with foreign sales revenue reaching 797 million yuan, a year-on-year increase of 23.74%, accounting for 52.82% of total revenue [3]. - The company has shown strong growth in its anesthesia and urology product lines, with revenues of 477 million yuan and 216 million yuan, respectively, while nursing and catheter products also saw significant growth [3]. Financial Summary - The company’s revenue is projected to grow from 1.753 billion yuan in 2025 to 2.438 billion yuan in 2027, with year-on-year growth rates of 16.1%, 17.6%, and 18.2% respectively [4]. - The net profit attributable to the parent company is expected to increase from 264 million yuan in 2025 to 399 million yuan in 2027, with growth rates of 20.3%, 22.9%, and 23.1% [4]. - The gross margin for 2024 was reported at 44.53%, a decrease of 1.36 percentage points year-on-year, primarily due to the higher proportion of lower-margin overseas sales [3][4]. - The company has effectively controlled expenses, leading to an increase in the net profit margin to 15.14%, up 0.4 percentage points year-on-year [3].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook on the company's performance and growth potential [1][3]. Core Viewpoints - The company has ended inventory destocking with significant localization effects and is experiencing high growth in overseas markets. However, domestic sales are impacted by medical industry regulations, leading to a slowdown in growth [3]. - In 2024, the company achieved a revenue of 1.509 billion yuan, a year-on-year increase of 8.76%, and a net profit attributable to the parent company of 219 million yuan, up 13.98% year-on-year [1]. - The company is expanding its production base in Mexico and exploring markets in Europe, South America, and Southeast Asia, resulting in a 23.74% year-on-year increase in foreign sales revenue, which now accounts for 52.82% of total revenue [3]. - The company’s product lines, particularly anesthesia and urology products, are showing stable growth, with revenues of 477 million yuan and 216 million yuan respectively [3]. - The company is focusing on innovation and increasing R&D investment, which is expected to enhance its product line and improve profit margins [3]. Financial Summary - The company’s total revenue for 2024 is projected to be 1.753 billion yuan, with a year-on-year growth rate of 16.1% for 2025, reaching 2.062 billion yuan in 2026 and 2.438 billion yuan in 2027 [4]. - The net profit attributable to the parent company is expected to grow from 264 million yuan in 2025 to 399 million yuan in 2027, reflecting a compound annual growth rate of 20.3% to 23.1% [4]. - The gross margin for 2024 is reported at 44.53%, with a slight decrease attributed to the higher proportion of lower-margin overseas sales [3][4]. - The company’s sales net profit margin improved to 15.14% in 2024, indicating effective cost control measures [3]. Market and Business Outlook - The company is expected to maintain a steady growth trend as domestic demand recovers and overseas markets continue to expand [3]. - The report anticipates that the introduction of new products will not only diversify the product line but also optimize the product structure, potentially enhancing profitability [3].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月21日， 康德莱 发布了2024年年报。 # 财务与市场表现 # 主营业务与商业模式 康德莱的主要业务包括 医用穿刺针、医用输注器械等医疗器械的研发、生产、销售和服务 。其商业模式主要 以自有品牌产品销售为主，同时提供相关的医疗器械服务。2024年，公司营业收入为22.61亿元，同比下降 7.79%。这一下降主要源于市场环境的变化，导致公司产品销售受到一定影响。 # 综合分析 医疗器械行业整体市场规模持续增长，但市场竞争也日益激烈。尤其是在医疗器械集中带量采购常态化的背景 下，康德莱的市场份额和盈利能力受到一定挤压。尽管如此，康德莱通过调整经营策略、优化成本结构和推进 新产品上市等措施，试图稳住基本盘。 康德莱的核心驱动力在于其持续的研发投入和产品创新。 2024年，公司扣非净利润为2.11亿元，同比下降 5.44%。尽管面临营收和利润的下滑，但公司在自有产品业务上仍略有增长。此外，公司在医疗器械行业标 准制修订加速的背景下，积极提升产品质量，推动技术创新。 # 关于康德莱 康 ...

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月21日， 康德莱 发布了2024年年报。 # 财务与市场表现 # 主营业务与商业模式 康德莱的主要业务包括 医用穿刺针、医用输注器械等医疗器械的研发、生产、销售和服务 。其商业模式主要 以自有品牌产品销售为主，同时提供相关的医疗器械服务。2024年，公司营业收入为22.61亿元，同比下降 7.79%。这一下降主要源于市场环境的变化，导致公司产品销售受到一定影响。 # 综合分析 医疗器械行业整体市场规模持续增长，但市场竞争也日益激烈。尤其是在医疗器械集中带量采购常态化的背景 下，康德莱的市场份额和盈利能力受到一定挤压。尽管如此，康德莱通过调整经营策略、优化成本结构和推进 新产品上市等措施，试图稳住基本盘。 康德莱的核心驱动力在于其持续的研发投入和产品创新。 2024年，公司扣非净利润为2.11亿元，同比下降 5.44%。尽管面临营收和利润的下滑，但公司在自有产品业务上仍略有增长。此外，公司在医疗器械行业标 准制修订加速的背景下，积极提升产品质量，推动技术创新。 # 关于康德莱 营 ...

五洲医疗收盘上涨3.41%，滚动市盈率45.71倍，总 市值18.54亿元 3月26日，五洲医疗今日收盘27.26元，上涨3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到45.71倍，总市值18.54亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.14倍，行业中值31.99倍，五洲医疗排 名第87位。 股东方面，截至2025年3月10日，五洲医疗股东户数6536户，较上次增加139户，户均持股市值35.28万 元，户均持股数量2.76万股。 安徽宏宇五洲医疗器械股份有限公司的主营业务为一次性使用无菌输注类医疗器械的研发、生产和销 售，以及其他诊断护理等相关医疗用品的集成供应。公司主要产品有注射器、输液输血器、医用穿刺 针、其他诊断和临床护理产品四个系列。公司已经获得国家高新技术企业、安徽省企业技术中心、安徽 省省级工业设计中心等认定，并建立了完善的质量管理体系，且已获得了德国南德意志集团 (TüVSüD)ISO13485:2016医疗器械质量管理体系认证、欧盟CE产品认证、美国FDA企业注册和产品列 名。 最新一期业绩显示，2024年三季报，公司实现营业收入3.43 ...